News Center
News Type
7 Qingfeng Pharmaceutical Products Win Bids at the 10th National Drug Centralized Procurement
On December 12, the bidding for the 10th batch of the National Organized Drug Centralized Procurement officially began.
Great News! Two Qingfeng Pharmaceutical Products Included in the 2024 National Medical Insurance Catalog
On November 28, the National Healthcare Security Administration (NHSA) announced the results of the 2024 adjustments to the National Medical Insurance Drug List. Qingfeng Pharmaceutical’s Aurantii Fructus Immaturus Total Flavonoids tablets and QingRuiTan® Brivaracetam Tablets were officially included.
Qingfeng Pharmaceutical's First Shipment of Ibrutinib Mesylate Injection Exported to the U.S.
At 11:18 AM on October 25, 2024, the shipment ceremony for Qingfeng Pharmaceutical's Ibrutinib Mesylate Injection for export to the United States was held in Chengdu, marking a significant milestone in the company’s international journey.
56th Place! Qingfeng Pharmaceutical Ranks Once Again in China's top 100 Pharmaceutical Industry
On September 7, 2024, the 41st National Pharmaceutical Industry Information Annual Conference opened in Chengdu, Sichuan. At the conference, the Ministry of Industry and Information Technology released its highly anticipated 2023 “China's top 100 Pharmaceutical Industry”, with Qingfeng Pharmaceutical ranking 56th, up 24 spots from last year.
Qingfeng Pharmaceutical's Eribulin Mesilate Injection Approved for Marketing in the U.S.
On June 28, the Eribulin Mesilate Injection developed by Qingfeng Pharmaceutical Group was approved for marketing by the U.S. Food and Drug Administration (FDA).
First in China! Qingfeng Pharmaceutical's Brivaracetam Tablets Approved for Marketing
On June 28, the Brivaracetam tablets (trade name: Qingruitan®) developed by Qingfeng Pharmaceutical Group were officially approved for marketing by the National Medical Products Administration. The approval of Brivaracetam tablets fills a domestic gap, provides another powerful tool for the treatment of epilepsy in my country, and brings new options to epilepsy patients and their families.
